More than $100 million in bond funds and a new continuing levy passed in 2023 aren't enough to maintain the library's ...
For patients living with CML, every diagnosis marks the start of a journey shaped by fear, resilience and, above all, hope.
Cambridge-headquartered Cycle Pharmaceuticals has launched PHYRAGO, its first oncology product, in the US where it has ...
Stinger fit right in as the Blue Jackets and Columbus Metropolitan Library debuted a special way to enhance a great ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial ...
Scientists from King's College London have successfully applied a new technology that disarms one of the most potent weapons ...
Scientists from King's have successfully applied a new technology that disarms one of the most potent weapons cancer cells ...
Detailed price information for Enliven Therapeutics Inc (ELVN-Q) from The Globe and Mail including charting and trades.
Detailed price information for Enliven Therapeutics Inc (ELVN-Q) from The Globe and Mail including charting and trades.
TipRanks on MSN
Ascentage Pharma’s Phase 3 Study on Olverembatinib: A Potential Game-Changer for CML Treatment
Ascentage Pharma Group International (($HK:6855)) announced an update on their ongoing clinical study. Study Overview: Ascentage Pharma Group Inc.
The Columbus Metropolitan Library purchases over 400,000 books per year for its 23 branches in Franklin County.
The 'Freedom from Cancer' project provides free treatment for 200 blood cancer patients, ensuring long-term remission and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results